USANA Health Sciences, Inc. — Form 10-K Summary
Reporting period: Fiscal year ended January 3, 2015. Although the request metadata refers to “2013 Q4,” this filing reports fiscal 2014 results and includes the quarter ended January 3, 2015. Fiscal 2014 comprised 53 weeks, versus 52 weeks in fiscal 2013.
Business context and financial performance
USANA develops and manufactures nutritional and personal-care products sold through independent direct-selling Associates and Preferred Customers. It operated in 19 markets; 81.8% of fiscal 2014 sales were outside the United States. At year-end, it reported 349,000 active Associates and 81,000 active Preferred Customers.
| Metric | Fiscal 2014 | Fiscal 2013 |
|---|---|---|
| Net sales | $790.5 million | $718.2 million |
| Gross profit / margin | $649.7 million / 82.2% | $590.7 million / 82.3% |
| Operating earnings / margin | $116.1 million / 14.7% | $116.7 million / 16.3% |
| Net earnings / margin | $76.6 million / 9.7% | $79.0 million / 11.1% |
| Diluted earnings per share | $5.60 | $5.56 |
| Operating cash flow | $105.2 million | $98.9 million |
| Capital expenditures | $20.4 million | $8.1 million |
Cash and cash equivalents were $111.1 million at year-end, down from $137.3 million; working capital declined to $82.2 million from $133.2 million. The company had no debt outstanding at year-end. Its $75 million revolving credit facility expires in April 2016; guarantees reduced availability by approximately $4.6 million, and the company reported compliance with its covenants.
Changes versus the prior comparable period
- Sales rose 10.1% ($72.3 million), but management estimated the additional fiscal week contributed about $16.0 million. Unfavorable currency movements reduced sales by $14.9 million.
- Asia Pacific sales increased 17.6% to $536.7 million, led by Greater China, up 20.0% to $326.1 million. Americas and Europe sales declined 3.0% to $253.7 million. U.S. sales fell 8.8%; Canada and Mexico grew in local currency.
- Net earnings fell 3.0%, primarily as Associate incentives increased to 44.2% of sales from 42.9%, reflecting the 2013 compensation-plan changes and fourth-quarter promotions. Operating margin declined to 14.7% from 16.3%.
- Gross margin was nearly unchanged. SG&A increased $18.3 million, driven chiefly by wages and costs supporting growth, including in China. The effective tax rate rose to 33.7% from 32.2%.
- Diluted EPS edged up despite lower net earnings, as share repurchases reduced diluted shares outstanding. The company repurchased 1.9 million shares for $138.8 million during 2014.
Outlook, risks and unusual items
- Management expected Associate incentives to remain approximately 44% of sales in fiscal 2015, with modestly higher SG&A as it invests in product innovation, technology, and brand awareness. No specific sales or EPS guidance was provided.
- Management anticipated approximately $45 million of capital expenditures in 2015, including continued work on a China manufacturing facility expected to require about $40 million in total and become operational in the first half of 2016. About $18.6 million had been incurred through fiscal 2014.
- Management projected continued double-digit growth in Greater China, while identifying China licensing, product registration, and evolving direct-selling regulations as material uncertainties. China sales increased sharply, but Hong Kong continued to decline.
- Other key exposures include foreign-exchange movements, dependence on independent Associates and key sales leaders, product and advertising regulation, competition, supplier and shipping disruptions, and information-security risks. Late-2014 port congestion increased shipping costs and inventory lead times; management expected some effects to persist into mid-2015.
- A shareholder derivative lawsuit filed in August 2014 challenged certain February 2014 equity awards. The company moved to dismiss and stated it intended to defend the case. It recorded no contingency reserve, stating no contingency was considered probable and estimable; management did not expect a material effect.
- The company held an $8.5 million note receivable from a nutrition-bar supplier. A delayed supplier-facility project led to amended credit terms; management reported no impairment at year-end but said it would continue monitoring recoverability.
- Operating cash flow exceeded net earnings, but cash declined principally due to substantial share repurchases and facility investment. Management believed cash, operating cash flow, and available credit would cover ordinary operating and capital needs for the foreseeable future.
Important facts for investors to verify
- Separate underlying sales growth from the extra fiscal week and currency effects; assess whether customer and unit-volume growth is sustained.
- Track China sales concentration, licensing progress, regulatory compliance, and the trajectory of Hong Kong sales.
- Monitor Associate incentives, operating margins, and whether planned promotions and brand investments produce durable customer growth.
- Confirm capital-spending progress and funding needs for the China facility, and assess the supplier note’s repayment and impairment risk.
- Review liquidity after buybacks and investment, revolver availability and covenant terms, and the status of the derivative lawsuit.